NCO-700

NCO-700 is a dual cathepsin B and calcium-activated neutral protease (CANP) inhibitor with IC50 values of 0.8 and 46 μM, respectively. NCO-700 reduces the degradation of myocardial fibrin by inhibiting protease activity. NCO-700 also has inhibitory effects on hormone-independent tumor cells, such as prostate cancer cells, and induces apoptosis. NCO-700 can be used to study myocardial ischemia and refractory hormone-independent tumors[1][2].

Product Specifications

CAS Number

[84518-80-9]

UNSPSC

12352005

Target

Apoptosis; Cathepsin

Related Pathways

Apoptosis; Metabolic Enzyme/Protease

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Cardiovascular Disease

Smiles

O=C(N1CCN(CC2=C(C(OC)=C(OC)C=C2)OC)CC1)[C@H](CC(C)C)NC([C@H]3[C@H](C(OCC)=O)O3)=O

Molecular Formula

C26H39N3O8

Molecular Weight

521.60

References & Citations

[1]Toyo-oka T, et al. Reduction of experimentally produced acute myocardial infarction size by a new synthetic inhibitor, NCO-700, against calcium-activated neutral protease. Jpn Heart J. 1982 Sep;23 (5) :829-34. |[2]Eilon GF, et al. Tumor apoptosis induced by epoxide-containing piperazines, a new class of anti-cancer agents. Cancer Chemother Pharmacol. 2000;45 (3) :183-91. |[3]Sashida H, Abiko Y. Inhibition with NCO-700, a protease inhibitor, of degradation of cardiac myofibrillar proteins during ischemia in dogs. Biochem Pharmacol. 1985 Nov 1;34 (21) :3875-80.